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ABSTRACT
Of the more than 190 distinct species ofMycobacterium genus, many are economically and clinically important pathogens
of humans or animals. Among those mycobacteria that infect humans, three species namely Mycobacterium tuberculosis
(causative agent of tuberculosis), Mycobacterium leprae (causative agent of leprosy) and Mycobacterium abscessus
(causative agent of chronic pulmonary infections) pose concern to global public health. Although antibiotics have
been successfully developed to combat each of these, the emergence of drug-resistant strains is an increasing
challenge for treatment and drug discovery. Here we describe the impact of the rapid expansion of genome
sequencing and genome/pathway annotations that have greatly improved the progress of structure-guided drug
discovery. We focus on the applications of comparative genomics, metabolomics, evolutionary bioinformatics and
structural proteomics to identify potential drug targets. The opportunities and challenges for the design of drugs for
M. tuberculosis, M. leprae and M. abscessus to combat resistance are discussed.
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Mycobacteria: the global disease burden
Mycobacteria belong to the genus Mycobacterium,
which is the only genus representing theMycobacteria-
ceae family (order: Actinomycetales; class: Actinobac-
teria). The genus was proposed in 1896, to include
two species namely tubercle bacillus (now known as
Mycobacterium tuberculosis) and leprosy bacillus
(Mycobacterium leprae) [1]. Currently, there are >190
distinct species of Mycobacterium genus, some of
which are economically and clinically important
pathogens of humans or animals [2].
Among the human mycobacterial infections, those
caused by M. tuberculosis (tuberculosis), M. leprae
(leprosy) andMycobacteriumabscessus (chronic pulmon-
ary infections) pose a public health concern. Mycobacter-
ial infections aﬀect ∼11–14 million people each year
globally and tuberculosis (TB) alone is responsible for
∼1.3 million deaths each year, of which 374,000 were
people livingwithHIV/AIDS. In2016, 10.4millionpeople
living with HIV/AIDS, were diagnosed with TB [3].
In case of M. leprae infections, the World Health
Organization (WHO) reported ∼200,000 new cases
of leprosy each year (http://www.who.int/wer/2017/
wer9235/en/). In 2016, 214,783 new cases of leprosy
were reported globally. India reported the highest
number (135,485) and Brazil 25,218 cases. Lack of
eﬀective early diagnostic tool(s), vaccines and limited
understanding of the patterns of transmission contrib-
ute to the ongoing incidence.
In addition to TB and leprosy, Non-Tuberculous
Mycobacteria (NTM), such as M. abscessus complex,
are emerging worldwide as the cause of chronic pul-
monary infections [4,5]. Incidence rates of pulmonary
infections due to NTM, vary greatly with geographical
regions. The global incidence remained 1.0–1.8 in a
population of 100,000, however, these rates are much
higher in the US, Western Paciﬁc and Canada [5].
The prevalence of NTMs has increased from 1.3% [6]
to 32.7% in Colorado, in cystic ﬁbrosis patients [7].
The growing challenge of antimicrobial
resistance
Thepast fewdecadeshave seen a “discovery void”pertain-
ing to antibacterial drug development, where very few
newmoleculeshavebeenpatentedor approved for clinical
use [8]. This is particularly true for drug discovery against
mycobacteria, where no new drugs that were speciﬁcally
developed for this purpose reached the clinic after the
early 1960s until recently [9]. Importantly, the emergence
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of resistance towards ﬁrst-line and second-line drugs
poses additional challenges to the development of suitable
drugs in each of M. tuberculosis, M. leprae and
M. abscessus. The approval of drugs and causes of resist-
ance have been systematically reviewed for
M. tuberculosis [10,11], M. abscessus [12] and M. leprae
[13]. Antibiotic resistance can arise due to physiological,
intrinsic or acquired factors [10,14]. The intrinsic resist-
ance is attributed to cell-wall permeability, drug eﬄux sys-
tems, drug targets with low aﬃnity and enzymes that
neutralize drugs in the cytoplasm. The acquired resistance
is conferred by chromosomal mutations.
Although the TB mortality rate is falling at ∼3% per
year globally, drug-resistant TB remains a continuing
threat [3]. The spread of drug-resistant strains of TB
(mono-resistant, multidrug-resistant, extensively
drug-resistant and totally drug-resistant) is alarmingly
high and accounted for 490,000 cases of multidrug-
resistant TB (MDR-TB) in 2016. Around 47% of the
MDR-TB cases are reported in Southeast Asia [15].
Increase in isoniazid-susceptible rifampin resistance
was also noted in 2016, with 110,000 cases globally.
The global burden of MDR-TB has recently increased
by >20% annually [16] and the treatment is successful
in only 50% of the MDR-TB cases. With the ongoing
transmission of the drug-resistant strains of
M. tuberculosis in communities, it is increasingly
important to research novel drug targets and identify
potential leads that can be expanded to new drugs.
Drug resistance in leprosy is diagnosed by the
mouse footpad method, which is time and labour-
intensive. Alternatively, mutations can be detected in
drug-resistance-determining regions of M. leprae
drug targets such as dihydropteroate synthase (for
the drug: dapsone), β subunit of RNA polymerase
(rifampin) and subunit A of DNA gyrase (oﬂoxacin).
As drug resistance has been suspected only in cases
that self-report at the hospital as a result of reactivation
or relapse in leprosy, the numbers are currently low;
however, these may increase if a ﬁeld-based surveil-
lance system is implemented.
M. abscessus is naturally resistant to many ﬁrst-line
antimicrobials, including all the current TB drugs. The
acquired resistance to aminoglycosides is known to be
due to mutations in genes such as rrs [12]. Likewise,
mutations in 23S rRNA and genes such as erm(41)
and rrl are known to cause macrolide resistance in
M. abscessus [17].
Thus, emergence of antibiotic-resistant strains and
rapid spread due to globalization poses a serious chal-
lenge to the global health [18]. Genomics has served as
an important milestone in bacterial drug discovery
[19,20]. It is now possible to understand causes of emer-
gence of antibiotic-resistant strains and to identify poten-
tial drug targets through combinatorial approaches
involving comparative genomics, metabolomics, phylo-
genomics, evolutionary and structural biology/bioinfor-
matics (Figure 1). Here we discuss the current status of
drug discovery research in each area, focusing on the
scope and applicability of computational approaches.
Availability of genome sequences and
annotation data: applications of
comparative genomic approaches to drug
discovery research
Comprehensive understanding of the organization of
mycobacterial genomes began in 1998 with the
Figure 1. From mycobacterial genomes to drug discovery. Post-genomic application areas in mycobacterial drug discovery such as
comparative genomics and structural biology/bioinformatics are shown.
110 V. P. Waman et al.
elucidation of the complete genome sequence of
M. tuberculosis [21,22]. The M. tuberculosis reference
genome (H37Rv strain) is 4.41 Mbp in length and com-
prises 4081 protein genes, 13 pseudogenes, 45 tRNA
genes, 30 ncRNA, 3 rRNA genes and 2 miscRNA
genes (http://svitsrv8.epﬂ.ch/tuberculist/).
The genome ofM. leprae was ﬁrst sequenced in 2001
[23]. This 3.2 Mbp genome has signiﬁcant sequence
similarity with that of M. tuberculosis; however,
M. leprae reductively evolved to survive with 1614
protein genes, 1310 pseudogenes, 45 tRNA genes, 3
rRNA genes and 2 stable RNA genes (http://svitsrv8.
epﬂ.ch/mycobrowser/leprosy.html).
The complete genome of M. abscessus strain ATCC
19977 was ﬁrst sequenced in 2008 [24]. The 5.06 Mbp
genome consists of 4941 genes encoding 2886 proteins
with functional assignments and 2055 hypothetical
proteins (https://www.patricbrc.org/view/Genome/
36809.5).
Rapid annotation of genomic data, leading to the
development of general purpose as well as specialized
resources, described in Supplementary Table 1, is pro-
viding important information pertinent to sequence,
structure, function, metabolic pathway, taxonomy
and drug resistance mutations.
Comparative genomics: understanding strain
diversity and emergence of drug-resistant
strains
Most pathogenic mycobacterium species including
M. tuberculosis and M. leprae are slow growers taking
>7 days to form visible colonies on solid media. Com-
parative pan-genomic analyses indicate that the evol-
ution of rapid and slow growers is attributed to a
series of gene gain and gene loss events leading to adap-
tation to diﬀerent environments [25]. Classical
methods for genotyping of mycobacterial strains
include IS6110DNA ﬁngerprinting, spoligotyping and
24 locus-MIRU (mycobacterial-interspersed repetitive
units)-VNTR (variable number of tandem repeats) typ-
ing [26]. With the availability of genome sequencing
data, complete genome-based phylogenies are being
used for genotyping and classiﬁcation of mycobacteria
[27,28]. The classical M. tuberculosis complex is subdi-
vided into seven distinct lineages with characteristic
geographic distribution [29]. Genomic analyses
revealed three subspecies of M. abscessus, namely M.
abscessus, M. massiliense and M. bolleti [30]. Likewise,
lineage diversity within distinct subtypes of M. leprae
has been recently studied based on phylogenomic ana-
lyses of 154 genomes [31].
Molecular phylogenetics and evolutionary
dynamics methods allow study of epidemiology and
links between genetic diversity and emergence of
drug resistance in mycobacterial strains [32]. Anti-
biotic-resistant genes are important markers for
delineation of evolution and spread of drug resistance
[10,14,33]. Such computational studies have helped to
answer speciﬁc questions such as: Whether a particu-
lar phylogenetic lineage is associated with drug resist-
ance in an outbreak/epidemic? When and how the
drug-resistant strains have emerged? What are the
evolutionary factors that cause antimicrobial drug
resistance in mycobacterium? Computational studies
on mycobacterium addressing each of these questions
are described below.
Recently, genomic studies focusing on population
structure, origin and spread of MDR-TB have been
undertaken across various parts of the world [29,34–
36]. A study [34] on strain diversity and phylogeogra-
phy using genomes of 340 M. tuberculosis strains (iso-
lated during 2008–2013) from KwaZulu-Natal, helped
to elucidate the timing of acquisitions of drug resist-
ance mutations that confer XDR-TB, indicating that
isoniazid-resistance evolved earlier than rifampicin-
resistance. Similarly, molecular epidemiology of
MDR-TB in Ireland has been systematically examined
using genomes of M. tuberculosis strains isolated
during 2001–2014 from MDR-TB cases [35]. Among
seven lineages of MTB complex, Beijing lineage was
observed to be associated with MDR [35]. MDR-TB
in Ireland was found to be introduced from other
localities, as known for several European countries
[37].
In the case of M. abscessus, phylogenomic studies
revealed the major role of recombination in causing
lineage diversity [30,38,39]. Population structure and
recombination analyses provided signiﬁcant evidence
of gene ﬂow and admixture among three lineages
(M. abscessus, M. massiliense, and M. bolleti), and a
correlation with pathogenicity and macrolide resist-
ance in cystic ﬁbrosis patients was found [39]. Phyloge-
nomic and genetic polymorphism analyses have also
been carried out using M. abscessus isolates from US
[40]. A population genomic study [41], based on the
worldwide collection of clinical isolates of
M. abscessus, has shown that the majority of
M. abscessus infections are acquired through trans-
mission (potentially via aerosols and fomites) of
recently emerged circulating clones that have spread
across the world. These clones are observed to be
associated with increased virulence and worse clinical
outcomes. This is a wake-up alarm! We are facing a
pressing international infection challenge [41].
In the case of M. leprae, a comprehensive study on
phylogenomics and antibiotic resistance has been
recently published [31], which focuses on sequence
and selection pressure analysis of wildtype as well as
antibiotic-resistant genes. Several attempts have also
been made to analyse the origin and spread of leprosy
across various parts of the world [42].
Thus, comparative genomics and phylogeographic
studies are important in understanding the global
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spread and transmission dynamics of the mycobacter-
ial infections. Strain diversity is shown to be one of the
contributing factors to antibiotic resistance, linking
transmission dynamics to medicine, across various
geographic areas which are endemic for diseases such
as TB [43]. Furthermore, all these developments
point to an increasing need for new and eﬀective
drugs to combat antibiotic resistance. Ideally, new
drugs must have a novel mode of action to reduce
events of cross-resistance, optimal dose-response,
pharmacokinetic and toxicity proﬁles allowing safe
and short duration of therapy either solely or in com-
bination with other drugs. Comparative genomics of
metabolic pathways provide a means to rapidly identify
potential gene targets and thus could aid in drug dis-
covery research (detailed in next section).
Comparative pathway analyses and
identiﬁcation of essential genes
M. tuberculosis, M. abscessus and M. leprae survive in
distinct ecological niches with distinct evolving features
that enable them to adapt to their speciﬁc environ-
ments. Malhotra et al. [44] describe a 90% overlap of
known and proposed drug targets against all mycobac-
terial species. The study identiﬁed the major pathways
such as chorismate, purine/pyrimidine and amino acid
biosynthetic pathways, essential for the survival of
mycobacteria, as conserved in all these three species
with minor diﬀerences in the carbon metabolism
pathways.
M. tuberculosis is known for its peculiar ability to
survive in the human macrophage despite varying
stress conditions (redox, acidic, and nitrosamine)
within the host. This has contributed to a very elabor-
ate DNA repair and recombination system. The most
up-to-date metabolic reconstruction for
M. tuberculosis describes 1228 metabolic reactions,
1011 genes and 998 metabolites [45], where 250
protein-coding genes present in the lipid biosynthetic
pathways are responsible for the thick cell wall.
Mutations in these pathways give rise to further
changes in their metabolic pathways.
Draft metabolic reconstruction for M. abscessus
exists in BioCyc [46] and KEGG [47] databases, with
110 pathways including biosynthesis, metabolism, bio-
degradation and information processing pathways.
Evolutionary analyses showed that M. abscessus is
more closely related to other NTMs such as
M. avium complex and has a well-supported mem-
brane transport system with a large number of eﬄux
pumps, resulting in multidrug-resistant features [48].
As an opportunistic bacterium, M. abscessus is able to
survive outside its host and also contains metabolic
pathways not associated with pathogenesis, which con-
tribute to its larger genome size as compared to obligate
pathogens.
In case of M. leprae, reductive evolution has led to
the loss of common catabolic pathways such as lipoly-
sis and impairment of the energy metabolism pathways
[23]. Moreover, the production of cognate and prosthe-
tic groups from transport, biosynthetic and electron
transfer pathways is also aﬀected [49]. With the loss
of several functions, and the presence of a large number
of conserved but unknown functions of pseudogenes,
further studies to characterize the metabolic pathways
in M. leprae are required.
Approaches to identify essential genes and
prioritization of drug targets
The availability of genome sequences of mycobacteria,
and annotations in sequence, structure and pathway
databases facilitate systems-level analysis wherein com-
parative genomics and evolutionary bioinformatics
approaches can be integrated to identify the minimal
set of essential genes, leading to faster identiﬁcation
of putative drug targets. Essential genes that are necess-
ary for the survival of the bacterium, and are critical
components of metabolic and physico-chemical path-
ways, can be identiﬁed by gene knockouts, saturation
transposon mutagenesis, RNA interference, etc. Essen-
tial genes have been characterized experimentally in
the case of M. tuberculosis [50–52]. However, limited
studies have been carried out in M. abscessus and
M. leprae. Speciﬁcally, M. leprae cannot be cultured
in vitro and thus demands computational identiﬁcation
of essential genes.
Computational approaches for identiﬁcation of
essential genes, including machine learning, ﬂux bal-
ance analyses and comparative genomics [53], are fas-
ter and cheaper than experimental methods [53].
Machine learning methods utilize unique genomic fea-
tures of essential genes such as length of proteins,
codon usage, GC content, sub-cellular localization,
higher rate of evolutionary conservation, etc. Dedicated
resources such as Database of Essential Genes [54] and
the database of Online Gene Essentiality [55] have been
developed, which serve as a platform for identiﬁcation
and prioritization of essential drug targets in various
species includingM. leprae [56]. Advent of next-gener-
ation sequencing has enabled design of comparative
genomics workﬂows to identify essential genes in
case of M. tuberculosis [57].
Upon identiﬁcation of a set of essential genes, prior-
itization of drug targets can be achieved by further
screening of essential genes based on computational
predictions of ADMET (absorption, distribution,
metabolism, excretion and toxicity) properties, sub-cel-
lular localization, etc. In view of growing concern about
drug resistance, attempts have been made to prioritize
drug targets based on various analyses such as identiﬁ-
cation of uniqueness in metabolome and similarities to
known druggable proteins, analysis of the protein-
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protein interactome, ﬂux balance analysis of reactome
and sequence-structural analysis of targetability of
genes using integrative strategies [58,59]. As most criti-
cal targets in a pathogenic organism are expected to be
evolutionarily conserved, this has been applied to ﬁlter
essential genes in M. tuberculosis [58]. Likewise, con-
vergent positive selection analyses were used to identify
genes that possibly cause drug resistance in
M. tuberculosis [59]. Evolutionary rate has been pro-
posed as a useful parameter for ranking and prioritiz-
ing antibacterial drug targets [60]. Thus,
understanding evolution of drug targets is one of the
important aspects of the drug discovery, especially to
tackle the problem of drug resistance.
Structural biology and bioinformatics to
combat mycobacterial infections
Early approaches to the discovery of new antibiotics
relied almost entirely on whole-cell phenotypic screen-
ing of natural products, microbial extracts and fermen-
tation broths. This approach has helped in the
discovery of most antibiotics in use to date and recently
led to the approval of two new drugs, bedaquiline and
delamanid, for the treatment of drug-resistant strains
of TB [61]. Structure-guided drug discovery, pioneered
in academia and some companies in the 1970s became
central to the discovery of antihypertensives that tar-
geted renin and AIDS antivirals that targeted HIV pro-
tease in the 1980s and 1990s [62–64]. Opportunities for
structure-guided drug discovery of mycobacterial tar-
gets became real only later when genome sequences
became available. Understanding the structure and
mechanism of the target allowed progress and optimiz-
ation of hit-to-lead molecules, as well as a better under-
standing of resistance mechanisms, identifying causes
of potential side eﬀects and drug-drug interactions.
This understanding led many research groups to per-
form high-throughput screening (HTS) and frag-
ment-based screening campaigns of chemical libraries
[65] directly against carefully selected targets of inter-
est. The applications of structure-guided drug discov-
ery to mycobacteria have been reviewed earlier
[66–68].
Structural features can also be used to further reﬁne
target selection and validation including lack of struc-
tural homology to human host to avoid mechanism-
based toxicity and ligandability leading to modulation
of target activity. Where the target protein has not
been structurally or functionally characterized, it’s
structural model can be built based on homologous
proteins using programs like MODELLER [69].
Important information regarding target protein func-
tion and properties can be obtained from databases
such as TubercuList (http://svitsrv8.epﬂ.ch/
tuberculist/) or CHOPIN [70]. Further, druggability
of targets can be predicted by analysing properties
and depths of various pockets/hotspots (capable of
small-molecule binding interactions), using several
databases and programs [71].
Fragment-based drug discovery (FBDD): a
promising alternative to HTS approach
The principal advantage of the FBDD approach com-
pared to HTS methods is that very small libraries
(<103 fragments) of low molecular weight (<300 Da)
compounds can be used to obtain good starting points
for lead discovery [65]. Initial fragment hits usually
exhibit lower potency than the more complex mol-
ecules found in typical HTS compound libraries, but
can be chemically optimized into lead candidates,
thereby more eﬀectively exploring the chemical space
available for binding to the target protein [68]. Figure 2
illustrates a typical fragment screening cascade
employed in our lab. The details of these steps are sum-
marized in Supplementary File 1.
FBDD approaches have been successfully applied to
design inhibitors targeting various key M. tuberculosis
enzymes such as pantothenate synthetase [72], tran-
scriptional repressor [73], cytochrome P450 [74], thy-
midylate kinase [75] and malate synthase [76]. Some
of the lead molecules developed from such fragment-
based campaigns showed promising inhibitory
response against M. tuberculosis, as shown in the
example in Supplementary Figure 1.
Virtual screening, hotspot mapping and
pharmacophore modelling to aid
structure-guided drug discovery
In-silico screening and docking of compound
libraries often help to reduce the time and cost
involved in experimental testing of large sets of com-
pounds to identify potential hits. The eﬀectiveness
of such virtual screening exercises can be improved
by complementing the analysis with fragment
hotspot-mapping programs [71], which identify
regions within the protein that provide relatively
large contribution towards ligand binding in
addition to information on interactions governing
the predicted regions. Several studies [77,78] have
used an energy-based pharmacophore modelling
approach to complement virtual screening, followed
by chemical optimization to identify inhibitors. We
have collaborated with Maria Paola Costi at the Uni-
versity of Modena in a similar study involving a
combination of virtual screening and molecular
dynamics simulation methods to identify novel
chemical scaﬀolds targeting M. tuberculosis thymi-
dylate synthase X [79].
Phenotypic screening along with advances in chemi-
cal genetics and bioinformatics has allowed target-
guided compound identiﬁcation and optimization
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[80], by utilizing target mechanism-based whole-cell
screening or by genetic manipulation of the target phe-
notype, or by ﬁnding targets directly from phenotypic
hits [81]. The latter approach can employ various tech-
niques such as whole genome sequencing to identify
resistant mutants [82,83], transcriptional proﬁling
[84], chemical biology and metabolomics [85] or in-
silico methods [86]. These advances in the ﬁeld dis-
cussed above, coupled with a comprehensive under-
standing of the chemical space of mycobacterial
drugs, hold promise of accelerating the process of
mycobacterial drug discovery.
From genomes to proteomes: automated
modelling of proteomes through structural
genomics and bioinformatics
Methods to identify structures that are potentially simi-
lar to the protein in question (templates) have been
developed in our laboratory [87] and elsewhere
(reviewed in [88]), as well as methods such as MODEL-
LER [69] and Rosetta [89] to leverage this similarity to
build theoretical, comparative models based on target-
template alignments. Community-wide eﬀorts, such as
Critical Assessment Structure Prediction [90] have led
to substantial improvements in the accuracy of these
approaches, both in terms of template identiﬁcation
and alignment, as well as model building and reﬁne-
ment. However, most of these methods focus on pro-
ducing a single, most likely structure of each protein.
Our group has developed a structural genomics
resource for M. tuberculosis (H37Rv strain) called
CHOPIN [70] which provides an ensemble of pre-
dicted models in diﬀerent conformational states.
These models are generated through a homology mod-
elling pipeline. Development of such structural
resources is important to identify potential therapeutic
targets [91].
Moving beyond proteomes: understanding the
impact of drug-resistant mutations in drug
targets
Mutations are likely to confer drug resistance by alter-
ing the energy landscape of the target protein, aﬀect-
ing the protein-protein interactions or aﬀecting the
drug/ligand binding with the target protein. Compu-
tational approaches to predict the eﬀects of mutations
on the structure and function of proteins can prove
helpful in understanding the mechanism of drug
resistance. Our lab has developed two well-established
methods, SDM (Site Directed Mutator), based on a
statistical approach using Environment Speciﬁc Sub-
stitution Tables [92] and mCSM (mutation Cutoﬀ
Scanning Matrix), a machine learning approach [93]
to predict the structural and functional eﬀects of
mutations on the target proteins. mCSM is available
in diﬀerent ﬂavours to predict the eﬀects of mutations
on protein stability (mCSM-stability), protein-protein
interactions (mCSM-PPI) and protein-ligand inter-
actions (mCSM-lig) [94]. Additionally, in order to
determine the impact of mutations on ﬂexible protein
conformations, tools like EnCOM [95] and FoldX [96]
have been developed. Such methods have been used
by our group and others to gain insights into the
mechanism of mutations in various genetic and myco-
bacterial diseases including leprosy [97–100]. Such
analyses of the structural and functional mechanism
of drug resistance causing mutations using compu-
tational approaches are very helpful in the rapid
assessment of many mutations not easily achieved
using experimental methods.
Challenges and future perspectives
This review has focused on the importance of
advances in sequence and structure determination of
Figure 2. FBDD cascade. Various techniques involved in each of the four stages are shown.
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genomes and their protein products in eﬀorts to
develop structure-guided drug discovery against
three mycobacteria: M. tuberculosis, M. abscessus
and M. leprae. Although M. tuberculosis is the most
studied mycobacterium, 3D structures of only ∼16%
of gene products have been determined experimen-
tally. Sequence-structure homology recognition and
comparative modelling have proved useful in provid-
ing clues about druggability. Furthermore, the more
accurate models, based on structures of close homol-
ogues, can provide a basis for virtual screening and
ligand design.
Metabolic reconstructions are providing insights
into how M. tuberculosis has adapted within the host,
and similar studies in M. abscessus and M. leprae are
needed to provide better understanding of pathogen-
esis and design of new treatment regimes. The current
focus in many laboratories is on providing user-
friendly databases for the structural proteomes, and
extending these not only to structures of homo- and
hetero-oligomers, and complexes with natural and syn-
thetic ligands, but also to incorporate data onmetabolic
pathways and epistasis, which are important in target
selection.
The target-guided approach for antibiotic drug
development has generally led to a low rate of trans-
lation of in-vitro inhibitory response to bactericidal/
bacteriostatic activity. This challenge requires further
study not only of physico-chemical properties of com-
pounds aﬀecting permeability of the thick waxy cell
envelopes of mycobacteria, but also of drug eﬄux
pumps and metabolic inactivation of compounds by
bacterial/host cell enzymes that aﬀect compound bioa-
vailability. The emergence of drug resistance through
mutations in the target is also a growing challenge.
We have developed systematic mutagenesis studies
using our software with a view to identify regions
where drug design might be directed with a minimal
chance of resistance. This is likely to be a key com-
ponent in drug discovery in future, especially through
structure-guided fragment-based approaches, where
choices of fragment elaboration or cross-linking can
be made in the light of such analyses of mutability.
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